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New ﬂuorinated bent-core mesogens containing the 1,2,4-oxadiazole or 1,2,4-triazole nucleus have been
synthesized taking advantage of the ANRORC (Addition of Nucleophile, Ring-Opening, Ring-Closure)
reactivity of 5-perﬂuoroalkyl-1,2,4-oxadiazoles. Physical state changes of the obtained compounds were
characterized through DSC, POM, and SAXS. Besides the formation of a smectic mesophase, a novel
behavior as organic molecular glass was evidenced for some 1,2,4-oxadiazole derivatives.
J. Heterocyclic Chem., 00, 00 (2015).
I`NTRODUCTION
Achiral bent-core mesogens (BCMs) have stimulated a
new era in soft materials [1], because of their unique prop-
erties, such as chirality in the smectic phase [2]. The pres-
ence of mesophases in BCMs depends on the presence of
(hetero)aromatic cores, and the increase of the bend angle
promoted by a rigid heterocyclic ring has become a com-
mon feature of BCM design [3]. In particular, the increase
of the bent angle was achieved by replacing the phenyl ring
with substituted azoles [4].
Among these, 1,2,4-oxadiazoles have recently attracted
attention [5] due their ability to show a ferroelectric-like
polar switching and induced biaxiality [6]. 1,2,4-
Oxadiazole derivatives are more frequently studied for
their application in synthesis [7] and in medicinal chemis-
try [8]. However, this heterocycle shows great potential
for applications in advanced materials [9] also because of
its tendency to self-assembly when associated with
perﬂuoroalkyl chains [10]. Interestingly, while the intro-
duction of ﬂuorinated moieties is widely considered for
the design of Liquid Crystals (LC) [11] the design of ﬂuo-
rinated 1,2,4-oxadiazole-based BCMs is still unexplored.
Moreover, by exploiting the ANRORC (Addition of
Nucleophile, Ring-Opening, Ring-Closure) [12] reactivity
of 5-perﬂuoroalkyl-1,2,4-oxadiazoles [13], both the
3-perﬂuoroalkyl regioisomers, and the corresponding
ﬂuorinated 1,2,4-triazoles, are easily accessible. Starting
from these considerations, we decided to explore the syn-
thesis and preliminary characterization of ﬂuorinated ﬁve-
ring BCMs of general formula 1, which differs for the na-
ture of the heterocyclic rings as well as for the length of the
terminal ﬂuorinated tails (Fig. F11).
RESULTS AND DISCUSSION
All heterocyclic systems were obtained through key
oxadiazolic precursors 3a,b, which were easily synthesized
by following the amidoxime-route [7e] starting from deriv-
ative 2 with the appropriate perﬂuoroalkanoyl chloride
(Scheme S11) [13b].
ANRORC reactions of compounds 3a,b were performed
with different bidentate nucleophiles to obtain of regio-
isomeric oxadiazoles 3c,d and triazoles 3e,f by using hy-
droxylamine and (methyl)hydrazine, respectively (Scheme
1). All compounds were obtained in good to excellent
yields and easily puriﬁed by means of column chromatog-
raphy. Subsequently, compounds 3a–f were converted into
the corresponding phenol derivatives 4a–f after treatment
with boron tribromide under reﬂux (Scheme S22).
All compounds were obtained in excellent yields except
for triazole 4f, which decomposes under reaction condi-
tions. Nevertheless, by following a different strategy,
© 2015 HeteroCorporation
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hydrazinolysis of demethylated compound 4a, gave
directly desired compound 4f in good yield (SchemeS3 3).
Moreover, methylation of triazole 4f, by using
diazomethane as methylating agent, gave a mixture of
regio-isomers 4e and 4g with the latter as major product
(Scheme 3), in a regio-complementary way to the
hydrazinolysis of 1,2,4-oxadiazoles [13d].
A double coupling reaction was performed on the complete
set of ﬂuorinated azoles 4a–gwith 5-methoxyisophtalic acid 5
in the presence of DCC (SchemeS4 4). Desired compounds 1a–g
were obtained in fair to good yields and puriﬁed by column
chromatography.
BCMs 1a–g were characterized by means of Differential
Scanning Calorimetry (DSC) and the phases and transition
temperatures of the obtained compounds are summarized
in Table T11 and represented in Figure F22. For compounds
1a and 1d a mesogenic behavior was evidenced on
cooling, showing the presence of a mesophase under
100°C for both compounds. Interestingly, compound 1b
behaves as an organic glass, nearly at room temperature.
Organic glass attracted many researchers for their applica-
tions in the ﬁeld of materials chemistry [14]. At the best of
our knowledge this is the ﬁrst example of a small molecule
forming a ﬂuorinated organic glass. Unfortunately, com-
pounds 1c, 1e, and 1f showed decomposition after the ﬁrst
heating, while for compound 1g we did not observe any
mesophase transition.
In order to investigate the nature of the mesophase, anal-
ysis through Polarized Optical Microscopy (POM) was
performed on a non-oriented sample of BCM 1a, revealing
a schlieren texture, which by comparison with previously
reported textures [15], allowed the assignment of a polar
Smectic C phase (SmCP) as showed in Figure F33.
The effective presence of a tilted layered phase was con-
ﬁrmed by Small Angle X-ray Scattering (SAXS) experi-
ments performed on representative compound 1a as a
function of temperature (Fig. F44). In fact, the crystalline
sample presents sharp Bragg’s diffraction peaks, from the
ﬁrst to the third order, revealing a d spacing of 40Å, a
value which perfectly ﬁts the length of the fully elongated
mesogen 1a (Fig. 4, dotted line) [16]. The diffraction pat-
tern of the mesophase was evidenced on cooling the isotro-
pic liquid below 85°C (Fig. 4, solid line), revealing a
reduced d spacing of about 32Å, conﬁrming the presence
of a tilted Smectic phase.
Moreover, emission spectra recorded in acetonitrile evi-
denced an enhancement of ﬂuorescence emission for repre-
sentative BCMs 1 in comparison with the oxadiazoles 3.
While the different substitution pattern among compounds
1 did not affect the maxima position (Fig. F55).
Figure 1. General structure of synthesized BCMs 1.
Scheme 1. Synthetic pathways for the obtainment of compounds 3a–f.
Scheme 2. Synthesis of phenols 4a–f.
Scheme 3. Synthetic pathways for triazoles 4e–g.
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CONCLUSIONS
New ﬂuorinated BCMs containing different azoles were
synthesized by taking advantage of the ANRORC reactiv-
ity of ﬂuorinated 1,2,4-oxadiazoles. All compounds were
characterized as potential mesogens, and for two
compounds (1a and 1d) the presence of a smectic phase
was observed. Moreover, the formation of the ﬁrst ﬂuori-
nated organic glass was evidenced upon cooling of com-
pound 1b. This issue highlights the potential role of the
perﬂuorinated 1,2,4-oxadiazolyl moieties as a molecular
tool for reducing structural order. Therefore, these com-
pounds with the newly reported oxadiazolic platform could
represent a starting point for the development of new func-
tional materials.
EXPERIMENTAL SECTION
General. Melting points were determined on a hot-stage
apparatus and are uncorrected. 1H-NMR spectra were
recorded at 300MHz, residual solvent peak was used as
reference. Fluorescence emission spectra were registered in
acetonitrile solution (10μM) in the range of 275–450nm
Scheme 4. Synthesis of BCMs 1a–g.
Figure 2. DSC traces of second heating–cooling cycle (10°C/min) ofQ1 compound 1a (left) and compound 1b (right).
Table 1
Phase transition of compounds 1a–g.
Compound
Phase transitionsa
T (ΔH, ΔS)b
Heating Cooling
1a Cr 102.2 (40.5,
107.9) I
I 90.8 (1.8, 4.9) SmCP 80.3
(28.2, 79.8) Cr
1b Cr 81.9 (26.4,
74.4) I
I 37.9 G
1c Cr 109 dec.c ND
1d Cr 147.6 (35.2,
83.6) I
I 98.8 (2.1, 5.6) SmCP 86.9
(21.0, 58.5) Cr
1e Cr 40.4 dec.c ND
1f Cr 207.9 dec.c ND
1g Cr 159.3 (41.3,
95.4) I
I 143.9 (40.5, 97.1) Cr
aPhase transition temperatures were obtained from second cycle of
heating–cooling (10°C/min); Abbreviations: Cr = crystalline solid,
I = isotropic liquid, SmCP = polar smectic C phase, G = glass, dec. = de-
composition, ND = not determined.
bT (°C), ΔH (kJ·mol1), ΔS (J·mol1·K1).
cDecomposition occurs after ﬁrst cycle of heating.
Figure 3. Representative POMmicrophotograph (100×) for the texture of
the smectic phase of compound 1a at T = 85°C, on cooling.
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using an excitation wavelength of 250nm. The widths of the
slits were set at 1.5 and 1.0nm for excitation and emission,
respectively. DSC and POM measurements on non-
oriented samples were performed with 10°C/min ramp for
heating and cooling cycles. SAXS measurements on non-
oriented samples were performed at ID02 beamline at the
European Synchrotron Radiation Facility (ESRF) in
Grenoble, France, with 10°C/min ramp for heating and
cooling cycles. Chromatography was performed by using
silica gel (0.040–0.063mm) and mixtures of ethyl acetate
and petroleum ether (fraction boiling in the range of 40–
60°C) in various ratios (v/v). All solvent and reagents were
used as received. Compounds 2 [13b], 3a [13b], and 3c
[13b] were obtained as previously reported. All compounds
were obtained as white solids.
Synthesis of oxadiazole (3b). To a suspension of
amidoxime 2 (2g, 12.04mmol) in toluene (100mL), pyridine
(1.1mL, 13.6mmol) and perﬂuorobutyryl chloride (2mL,
13.39mmol) were added. The mixture was reﬂuxed for 2h
and cooled to rt. The solvent was removed under reduced
pressure and the residue chromatographed giving 3b (84%).
3-(4-Methoxyphenyl)-5-perﬂuoropropyl-1,2,4-oxadiazole
(3b). mp: 59–60°C. FT-IR (nujol) ν: 1614, 1576 cm1.
1H NMR(300MHz, CDCl3) δ: 3.90 (s, 3H, OCH3), 7.02
(d, J=9.0Hz, 2H, Ar), 8.1 (d, J=9.0Hz, 2H, Ar).
GC-MS (m/z): 344 (M+, 100%). Anal. Calcd. for
C12H7F7N2O2: C, 41.88; H, 2.05; N, 8.14. Found: C,
41.95; H, 2.00; N, 8.30.
Synthesis of oxadiazole (3d). t-BuOK (1.80g, 16mmol)
was added to a solution hydroxylamine chlorhydrate (1.11g,
16mmol) in dry DMF (5mL). After 10min, compound 3b
(918mg, 2.67mmol) was added. The mixture was stirred at
rt for 72h. The suspension was treated with water (50mL)
and extracted with AcOEt (100mL). The organic fraction
was dried with Na2SO4, ﬁltered, and evaporated to dryness.
The residue was chromatographed giving 3d (76%).
5-(4-Methoxyphenyl)-3-perﬂuoropropyl-1,2,4-oxadiazole
(3d). mp: 47–50°C. FT-IR (nujol) ν: 1612, 1585,
1562cm1. 1H NMR (300MHz, CDCl3) δ: 3.98 (s, 3H,
OCH3), 7.11 (d, J=8.7Hz, 2H, Ar), 8.20 (d, J=8.7Hz, 2H,
Ar). GC-MS (m/z): 344 (M+, 100%). Anal. Calcd. for
C12H7F7N2O2: C, 41.88; H, 2.05; N, 8.14. Found: C, 41.90;
H, 1.95; N, 8.20.
Synthesis of triazole (3e). Compound 3a (985mg,
1.81mmol) was dissolved in dry DMF (3mL), then
methylhydrazine (1mL, 18.8mmol) was added. The solution
was stirred at rt for 4.5h, then treated with water (50mL),
and extracted with AcOEt (100mL). The organic fraction
was dried with Na2SO4, ﬁltered, and evaporated to dryness.
The residue was chromatographed giving 3e (93%).
5-(4-Methoxyphenyl)-1-methyl-3-perﬂuoroheptyl-1H-1,2,4-
triazole (3e). mp: 82–84°C. FT-IR (nujol) ν: 1614,
1582cm1. 1H NMR (300MHz, CDCl3) δ: 3.89 (s, 3H,
OCH3), 4.07 (s, 3H, NCH3), 7.04 (d, J=8.9Hz, 2H, Ar),
7.66 (d, J=8.9Hz, 2H, Ar). GC-MS (m/z): 557 (M+, 100%).
Anal. Calcd. for C17H10F15N3O: C, 36.64; H, 1.81; N, 7.54.
Found: C, 36.70; H, 1.90; N, 7.55.
Synthesis of triazole (3f). Compound 3a (500mg,
0.919mmol) was dissolved in dry DMF (3mL), then
hydrazine hydrate (223μL, 4.60mmol) was added. The
solution was stirred at rt for 4.5h, then treated with water
(25mL) and extracted with AcOEt (75mL). The organic
fraction was dried with Na2SO4, ﬁltered, and evaporated to
dryness. The residue was chromatographed giving 3f (86%).
5-(4-Methoxyphenyl)-3-perﬂuoroheptyl-1H-1,2,4-triazole
(3f). mp:150–151°C. FT-IR (nujol) ν: 1617cm1. 1HNMR
(300MHz, CDCl3) δ: 3.89 (s, 3H, OCH3), 7.03 (d, J=8.1Hz,
2H, Ar), 7.88 (d, J=8.1Hz, 2H, Ar). GC-MS (m/z): 543 (M+,
100%). Anal. Calcd. for C16H8F15N3O: C, 35.38; H, 1.48; N,
7.74. Found: C, 35.45; H, 1.50; N, 7,80.
Figure 5. Emission spectra of representative BCMs 1a,b,d and
oxadiazoles 3a,d.
Figure 4. SAXS spectra for compound 1a as crystalline solid at room
temperature (dotted line) and as LC at 85°C on cooling (solid line).
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Demethylation of azoles (3)
General procedure. To a solution of compound 3
(2mmol) in toluene (20mL), boron tribromide (10mmol,
10mL of solution 1M in hexane) was added, and the solu-
tion was reﬂuxed for 2 h. Then water (10mL) was added,
and toluene was removed under reduced pressure. The wa-
ter was extracted with AcOEt (100mL). The organic frac-
tion was dried with Na2SO4, ﬁltered, and evaporated to
dryness. The residue chromatographed giving compounds
4 (5–98%, see Scheme 2).
3-(4-Hydroxyphenyl)-5-perﬂuoroheptyl-1,2,4-oxadiazole
(4a). mp: 122–123°C. FT-IR (nujol) ν: 3416, 3285,
3200, 1616, 1587 cm1. 1H NMR (300MHz, DMSO-d6)
δ: 6.85 (d, J=11Hz, 2H, Ar), 7.78 (d, J=11Hz, 2H, Ar),
10.3 (s, H, exch. with D2O, OH). GC-MS (m/z): 530
(M+, 100%). Anal. Calcd. for C15H5F15N2O2: C, 33.98;
H, 0.95; N, 5.28. Found: C, 34.00; H, 1.05; N, 5.45.
3-(4-Hydroxyphenyl)-5-perﬂuoropropyl-1,2,4-oxadiazole
(4b). mp: 76–77°C. FT-IR (nujol) ν: 3354, 3196, 1614,
1605 cm1. 1H NMR (300MHz, CDCl3) δ: 5.58 (s, 1H,
exch. with D2O, OH), 6.96 (dd, J=6.9, 2.1Hz, 2H, Ar),
8.04 (dd, J=6.9, 2.1Hz, 2H, Ar). GC-MS (m/z): 330
(M+, 100%). Anal. Calcd. for C11H5F7N2O2: C, 40.02;
H, 1.53; N, 8.48. Found: C, 40.00; H, 1.55; N, 8.50.
5-(4-Hydroxyphenyl)-3-perﬂuoroheptyl-1,2,4-oxadiazole
(4c). mp: 106–108°C. FT-IR (nujol) ν: 3420, 1605,
1558 cm1. 1H NMR (300MHz, CDCl3) δ: 5.56 (s, 1H,
exch. with D2O, OH), 7.01 (d, J=8.7Hz, 2H, Ar), 8.12
(d, J=8.7Hz, 2H, Ar). GC-MS (m/z): 530 (M+, 100%).
Anal. Calcd. for C15H5F15N2O2: C, 33.98; H, 0.95; N,
5.28. Found: C, 34.11; H, 1.10; N, 5.33.
5-(4-Hydroxyphenyl)-3-perﬂuoropropyl-1,2,4-oxadiazole
(4d). mp: 63–65°C. FT-IR (nujol) ν: 3300, 1612, 1593,
1572 cm1. 1H NMR (300MHz, CDCl3) δ: 5.70 (s, 1H,
exch. with D2O, OH), 7.07 (d, J=8.7Hz, 2H, Ar), 8.18
(d, J=8.7Hz, 2H, Ar). GC-MS (m/z): 330 (M+, 100%).
Anal. Calcd. for C11H5F7N2O2: C, 40.02; H, 1.53; N,
8.48. Found: C, 40.00; H, 1.60; N, 8.45.
5-(4-Hydroxyphenyl)-1-methyl-3-perﬂuoroheptyl-1H-1,2,4-
triazole (4e). mp: 84–87°C. FT-IR (nujol) ν: 1614,
1593 cm1. 1H NMR (300MHz, CDCl3) δ: 4.13 (s, 3H,
NCH3), 7.01 (d, J=8.7Hz, 2H, Ar), 7.64 (d, J=8.7Hz,
2H, Ar). GC-MS (m/z): 543 (M+, 100%). Anal. Calcd.
for C16H8F15N3O: C, 35.38; H, 1.48; N, 7.74. Found: C,
35.30; H, 1.55; N, 7.85.
5-(4-Hydroxyphenyl)-3-perﬂuoroheptyl-1H-1,2,4-triazole
(4f). mp: 148–149°C. FT-IR (nujol) ν: 3275, 3192, 1616,
1597 cm1. 1H NMR (300MHz, DMSO-d6) δ: 6.98 (d,
J=8.7Hz, 2H, Ar), 7.92 (d, J=8.7Hz, 2H, Ar), 10.2 (s,
1H, exch. with D2O, OH), 15.1 (s, 1H, exch. with D2O,
NH). GC-MS (m/z): 529 (M+, 100%). Anal. Calcd. for
C15H6F15N3O: C, 34.04; H, 1.14; N, 7.94. Found: C,
34.05; H, 1.10; N, 7.90.
Synthesis of triazole (4f). Compound 4a (1g, 1.89mmol)
was dissolved in dry DMF (5mL), then hydrazine hydrate
(460μL, 9.48mmol) was added. The solution was stirred at
rt for 24h, then treated with water (50mL), and extracted
with AcOEt (100mL). The organic fraction was dried with
Na2SO4, ﬁltered, and evaporated to dryness. The residue
was chromatographed giving 4f (81%).
Synthesis of triazole (4g). 4f (300mg, 0.567mmol) was
dissolved in Et2O (20mL), then a diazomethane solution
was added until persistent yellow coloration. The solution
was left at rt overnight and then evaporated to dryness.
The residue was chromatographed giving 4g (69%) and
4e (23%).
3-(4-Hydroxyphenyl)-1-methyl-5-perﬂuoroheptyl-1H-1,2,4-
triazole (4g). mp: 144–146°C. FT-IR (nujol) ν: 3597,
3285, 3177, 1616 cm1. 1H NMR (300MHz, DMSO-d6)
δ: 4.07 (s, 3H, NCH3), 6.86 (d, J=8.4Hz, 2H, Ar), 7.81
(d, J=8.4Hz, 2H, Ar), 9.89 (s, 1H, exch. with D2O,
OH). GC-MS (m/z): 543 (M+, 100%). Anal. Calcd. for
C16H8F15N3O: C, 35.38; H, 1.48; N, 7.74. Found: C,
35.45; H, 1.50; N, 7.60.
Synthesis of bent-core esters (1)
General procedure. Compound 4 (0.70mmol) was dis-
solved in dry DMF (5mL), then DMAP (105mg,
0.85mmol), 5-metoxy-isophtalic acid (68mg, 0.35mmol),
and HOBt (92mg, 0.70mmol) were added, and the solution
was stirred at rt for 10min. Then a solution of DCC
(355mg, 1.7mmol) in dry DMF (3mL) was slowly added.
After 2 h the reaction mixture was diluted with AcOEt. The
formed precipitate was removed by ﬁltration, and the ﬁl-
trate was evaporated under reduced pressure. The residue
was chromatographed giving compound 1 (29–81%, see
Scheme 4).
Bis(4-(5-perﬂuoroheptyl-1,2,4-oxadiazol-3-yl)phenyl)-5-
methoxybenzene-1,3-dioate (1a). mp: 105–106°C. FT-IR
(nujol) ν: 1747, 1605 cm1. 1H NMR (300MHz, CDCl3)
δ: 3.99 (s, 3H, OCH3), 7.44 (d, J=8.5Hz, 4H, Ar), 8.01
(d, J=1.5Hz, 2H, Ar), 8.25 (d, J=8.5Hz, 4H, Ar), 8.64
(t, J=1.5Hz, 1H, Ar). ESI-MS (m/z): 1220 (M+, 100%).
Anal. Calcd. for C39H14F30N4O7: C, 38.38; H, 1.16; N,
4.59. Found: C, 38.30; H, 1.15; N, 4.65.
Bis(4-(5-perﬂuoropropyl-1,2,4-oxadiazol-3-yl)phenyl)-5-
methoxybenzene-1,3-dioate (1b). mp: 87–90°C. FT-IR
(nujol) ν: 1749, 1736, 1607cm1. 1H NMR (300MHz,
CDCl3) δ: 3.91 (s, 3H, OCH3), 7.36 (d, J=8.7Hz, 4H, Ar),
7.92 (d, J=1.4Hz, 2H, Ar), 8.17 (d, J=8.7Hz, 4H, Ar),
8.56 (t, J=1.4Hz, 1H, Ar). ESI-MS (m/z): 820 (M+, 100%).
Anal. Calcd. for: C31H14F14N4O7: C, 45.38; H, 1.72; N,
6.83. Found: C, 45.30; H, 1.85; N, 6.75.
Bis(4-(3-perﬂuoroheptyl-1,2,4-oxadiazol-5-yl)phenyl)-5-
methoxybenzene-1,3-dioate (1c). mp: 109–110°C. FT-IR
(nujol) ν: 1740, 1609, 1564cm1. 1H NMR (300MHz,
CDCl3) δ: 4.01 (s, 3H, OCH3), 7.52 (d, J=8.7Hz, 4H, Ar),
8.02 (s, 2H, Ar), 8.34 (d, J=8.7Hz, 4H, Ar), 8.65 (s, 1H,
Ar). ESI-MS (m/z): 1220 (M+, 100%). Anal. Calcd. for
C39H14F30N4O7: C, 38.38; H, 1.16; N, 4.59. Found: C,
38.25; H, 1.10; N, 4.55.
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Bis(4-(3-perﬂuoropropyl-1,2,4-oxadiazol-5-yl)phenyl)-5-
methoxybenzene-1,3-dioate (1d). p: 147–150°C. FT-IR
(nujol) ν: 1744, 1609, 1560cm1. 1H NMR (300MHz,
CDCl3) δ: 4.07 (s, 3H, OCH3), 7.58 (dd, J=7.2, 1.8Hz, 4H,
Ar), 8.08 (d, J=1.2Hz, 2H, Ar), 8.39 (dd, J=7.2, 1.8Hz,
4H, Ar), 8.70 (d, J=1.2Hz, 1H, Ar). ESI-MS (m/z): 820
(M+, 100%). Anal. Calcd. for C31H14F14N4O7: C, 45.38; H,
1.72; N, 6.83. Found: C, 45.44; H, 1.65; N, 7.12.
Bis(4-(1-methyl-3-perﬂuoroheptyl-1H-1,2,4-triazol-5-yl)
phenyl)-5-methoxybenzene-1,3-dioate (1e). mp: 40–44°C.
FT-IR (nujol) ν: 3462, 3395, 1917, 1732, 1599 cm1. 1H
NMR (300MHz, CDCl3) δ: 4.07 (s, 3H, OCH3), 4.21 (s,
6H, NCH3), 7.54 (d, J=8.7Hz, 4H, Ar), 7.92 (d,
J=8.7Hz, 4H, Ar), 8.08 (d, J=1.2Hz, 2H, Ar), 8.71 (t,
J=1.2Hz, 1H, Ar). ESI-MS (m/z): 1246 (M+, 100%).
Anal. Calcd. for C41H20F30N6O5: C, 39.50; H, 1.62; N,
6.74. Found: C, 39.75; H, 1.55; N, 6.70.
Bis(4-(3-perﬂuoroheptyl-1H-1,2,4-triazol-5-yl)phenyl)-5-
methoxybenzene-1,3-dioate (1f). mp: 207–210°C. FT-IR
(nujol) ν: 3314, 1717, 1653 cm1. 1H NMR (300MHz,
DMSO-d6) δ: 4.05 (s, 3H, OCH3), 7.66 (d, J=8.6Hz,
4H, Ar), 8.04 (s, 2H, Ar), 8.21 (d, J=8.6Hz, 4H, Ar),
8.49 (s, 1H, Ar), 15.54 (s, 2H, exch. with D2O, NH).
ESI-MS (m/z): 1218 (M+, 100%). Anal. Calcd. for
C39H16F30N6O5: C, 38.44; H, 1.32; N, 6.90. Found: C,
38.55; H, 1.25; N, 7.00.
Bis(4-(1-methyl-5-perﬂuoroheptyl-1H-1,2,4-triazol-3-yl)
phenyl)-5-methoxybenzene-1,3-dioate (1g). mp: 162–164°C.
FT-IR (nujol) ν: 1735, 1597cm1. 1H NMR (300MHz,
CDCl3) δ: 3.98 (s, 3H, OCH3), 4.13 (s, 6H, NCH3), 7.36
(dd, J=6.9, 2.1Hz, 4H, Ar), 7.99 (d, J=1.5Hz, 2H, Ar),
8.21 (dd, J=6.9, 2.1Hz, 4H, Ar), 8.65 (t, J=1.5Hz, 1H,
Ar). ESI-MS (m/z): 1246 (M+, 100%). Anal. Calcd. for
C41H20F30N6O5: C, 39.50; H, 1.62; N, 6.74. Found: C,
39.45; H, 1.55; N, 6.60.
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